ClinicalTrials.gov
public full text
Public Domain
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce. The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)#1114608
- Multi-Omics to Predict the Blood Pressure Response to Antihypertensives#967106
- Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib#426671
- Identification of drug-related cardiovascular risks: A comprehensive analysis using the FAERS database (2004–2024)#248066
- VicorderCS NIBP Validation Study to Review The Ability to Capture Blood Pressure Measurements#826320
Record · ID 854025
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive